ClinicalTrials.gg
CompletedNCT01970553Updated Apr 1, 2015

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

A Phase 1 interventional study of lurbinectedin (PM01183) and Gemcitabine in Specific Advanced Solid Tumors, sponsored by PharmaMar. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-01.

Sponsored by PharmaMar · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Phase I multicenter, open-label, clinical and pharmacokinetic study of PM01183 in combination with gemcitabine in non-heavily pretreated patients with selected advanced solid tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with gemcitabine, to characterize the safety profile and feasibility of this combination in patients with selected advanced solid tumors, to characterize the pharmacokinetics (PK), to obtain preliminary information on the clinical antitumor activity in non-heavily pretreated selected solid tumor patients and to evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed, in order to assess potential markers of response and/or resistance.

02

Conditions studied

  • Specific Advanced Solid Tumors

Browse trials for

Keywords

  • lurbinectedin
  • PM01183
  • tumors
  • cancer
  • Pharma Mar
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 47 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily written
  • Age: between 18 and 75 years (both inclusive)
  • (ECOG) performance status (PS) ≤ 1
  • ≥ 3 months
  • Patients with a histologically/ confirmed diagnosis of advanced disease of any of the following tumors:

    1. Breast cancer
    2. Epithelial ovarian cancer (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas)
    3. Stromal uterine sarcomas
    4. Non-small cell lung cancer (NSCLC)
    5. Platinum- or relapsed germ cell tumors
    6. Adenocarcinoma of the exocrine pancreas
    7. Biliary tract adenocarcinoma
    8. Adenocarcinoma or carcinoma of unknown primary site
    9. Advanced or unresectable mesothelioma
  • At least three weeks since the last anticancer therapy,including radiation therapy (RT)
  • Adequate bone marrow, renal, hepatic, and metabolic function
  • (LVEF) by echocardiography (ECHO) or multiple-gated acquisition (MUGA) within normal range (according to institutional standards).
  • Women of must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of throughout the treatment period and for six weeks after discontinuation of treatment.

Exclusion criteria

Exclusion Criteria:

  • Concomitant diseases/conditions:

    • History or presence of unstable angina, myocardial infarction, congestive heart failure, or valvular heart disease within last year.
    • Symptomatic or any uncontrolled arrhythmia
    • Ongoing chronic alcohol consumption, or cirrhosis
    • Active uncontrolled infection.
    • Known (HIV) infection.
    • Any other major illness that, in the Investigator's judgment
  • or involvement
  • Men or women of who are not using an effective method of
  • Patients who have had radiation therapy in more than 35% of the bone marrow
  • History of previous bone marrow and/or stem cell transplantation
  • Prior treatment with gemcitabine-containing therapy for advanced disease
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    lurbinectedin (PM01183) / gemcitabine

    Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle): - Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes, immediately followed by: - PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks

    Drug: lurbinectedin (PM01183) · Drug: Gemcitabine

Interventions

  • lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials

  • 1000 mg vial, powder for injectable solution

06

What researchers measure

Primary outcomes

  1. Recommended Dose (RD)

    The RD will be the highest dose level explored at which less than one third of evaluable patients experience a DLT during Cycle 1.

    Time frame: 19 months

Secondary outcomes

  1. Pharmacokinetics (PK) characterisation

    The dose-exposure relationships for maximum plasma concentration (Cmax) and area under the curve (AUC) will be evaluated.

    Time frame: 19 months

  2. Preliminary antitumor efficacy

    To obtain preliminary information on the clinical antitumor activity of this combination in non-heavily pretreated selected solid tumor patients

    Time frame: 29 months

  3. Pharmacogenomics (PGx)

    to identify molecular markers whose expression may be associated with the clinical outcome of patients. These molecular markers might allow the identification of those patients who will benefit from PM01183 and gemcitabine treatment, thus improving the health care by an individualized medicine.

    Time frame: 29 months

07

Study locations

3 sites
  • Hospital Universitario Madrid Sanchinarro
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • University College of London Hospital
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 28, 2013
Start
May 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Apr 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01970553
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Oct 28, 2013
Start date
May 2011
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Apr 1, 2015

Study contacts

Sergio Szyldergemajn, MD
study chair · Pharma Mar

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion